1188264-78-9

Basic information

• Product Name: TERT-BUTYL 3-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 3-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLATE;1-Boc-3-Hydroxy-4-Methylpiperidine;3-Hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1188264-78-9
• Molecular Formula: C11H21NO3
• Molecular Weight: 215.28934
• Mol File: 1188264-78-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 3-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLATE(1188264-78-9)
• EPA Substance Registry System: TERT-BUTYL 3-HYDROXY-4-METHYLPIPERIDINE-1-CARBOXYLATE(1188264-78-9)

Safety Data

• Hazardous Substances Data: 1188264-78-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is a chemical compound with the molecular formula C11H21NO3. It is a tertiary amine and ester derivative of piperidine. tert-butyl 3-Hydroxy-4-methylpiperidine-1-carboxylate is commonly used in organic synthesis and pharmaceutical research as a building block in the production of various pharmaceuticals and biologically active compounds. It has also been studied for its potential use in the treatment of neurological disorders, as it has shown some potential in modulating neurotransmitter levels in the brain. Furthermore, it is known for its role as an intermediate in the synthesis of novel chemical entities with potential pharmacological activities.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 374822-48-7 C₆H₁₃NO 
• 384338-20-9 (rac, trans)-1-benzyl-4-methyl-piperidin-3-ol 
• 1188264-78-9 rac-tert-butyl (3S,4R)-3-hydroxy-4-methylpiperidine-1-carboxylate 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 374794-74-8 (trans)-3-hydroxy-4-methyl-piperidine hydrochloride 
• 81474-43-3 (4R,5S)-5-(hydroxymethyl)-4-methyldihydrofuran-2(3H)-one 
• 88424-25-3 methyl (±)-(3-oxiran-2-yl)butanoate 
• 65371-40-6 trans-γ-iodomethyl-β-methyl-γ-butyrolactone 
• 75371-78-7 3-methyl-pent-4-enoic acid 
• 374822-48-7 C₆H₁₃NO 
• 179685-91-7 (4S,5S)-5-azidomethyl-4-methyl-4,5-dihydro-2(3H)-furanone 
• 176966-79-3 (4R,5S)-5-(tert-Butyl-diphenyl-silanyloxy)-4-methyl-2-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 176966-80-6 tert-butyl (5S)-5-(tert-butyldiphenylsilyloxy)-4-methyl-2H-2-oxo-5,6-dihydro-piperidine-1-carboxylate 

Downstream Products

• 1188264-78-9 (rac,cis)-3-Hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1188264-78-9 (-)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 37835-47-5 rac-(3S,4R)-1,4-dimethylpiperidin-3-ol 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 1259404-17-5 tasocitinib 
• 374794-77-1 tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate 

Relevant articles and documents

Synthesis of key intermediate for (+)-tofacitinib through CoIII(salen)-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate

An enantiopure piperidine, a key intermediate for the synthesis of (+)-tofacitinib, has been achieved in high optical purity (98% ee) from readily available crotyl alcohol. The key steps involved is a CoIII(salen)-OAc-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.